Results 61 to 70 of about 20,877 (256)
JEADV Clinical Practice, EarlyView.ABSTRACT Background Scleromyxedema (SMX) is a cutaneous mucinosis characterised by an abnormal accumulation of mucin in the skin and limited treatment options. Assessment of therapy response during treatment is challenging. Objectives Patients with SMX receiving high‐dose intravenous IVIg therapy were included to assess validity of the double modified ...
Julia K. Winkler, Alexander H. Enk
wiley +1 more source
JEADV Clinical Practice, EarlyView.ABSTRACT Paradoxical atopic dermatitis (AD) can arise during biologic therapy for psoriasis due to an immune‐axis imbalance. We describe a 47‐year‐old man who developed severe AD while receiving secukinumab, which was successfully managed with the addition of dupilumab, allowing long‐term control of both diseases.
So Yun Park +6 more
wiley +1 more source
Refractory Eczema as a Presenting Feature of Common Variable Immunodeficiency
JEADV Clinical Practice, EarlyView.ABSTRACT Common variable immunodeficiency (CVID) is the most prevalent symptomatic inborn error of immunity (IEI) in adults. It presents with recurrent infections and non‐infectious complications, including autoimmunity, lymphoproliferation and dermatitis.
Mercedes Sanchez‐Diaz +2 more
wiley +1 more source
HPV‐6 Positive Eruptive Verruca Vulgaris After Upadacitinib Initiation for Severe Atopic Dermatitis
JEADV Clinical Practice, EarlyView.ABSTRACT Oral JAK‐1 inhibitors for atopic dermatitis (AD) are associated with an increased risk of cutaneous viral infections, particularly herpes zoster. Emerging case reports further suggest a link to eruptive human papillomavirus (HPV) disease. A 23‐year‐old transgender man (female‐to‐male) with severe AD developed a rapidly disseminating eruption ...
Mohammed Shanshal +2 more
wiley +1 more source
Brentuximab Vedotin‐Induced Rash Sparing CD30‐Positive Mycosis Fungoides Lesions
JEADV Clinical Practice, EarlyView.ABSTRACT Brentuximab vedotin (BV) is an effective treatment for CD30‐positive lymphomas, including mycosis fungoides (MF). However, its use can be associated with various cutaneous adverse effects, including rashes. This case describes a 60‐year‐old male with stage IIB MF who developed a drug‐induced erythematous rash after three infusions of BV ...
Isabel Hariri +2 more
wiley +1 more source
Drug Reaction with eosinophilia and systemic symptoms with alopecia universalis and vitiligo
Medicina, 2021 Drug reactions with eosinophilia and systemic symptoms (DRESS) are rare and potentially fatal adverse hypersensitivity reaction to some drugs, especially anticonvulsants. The syndrome affects not only the skin but also other organs, especially the liver.
Ives Alexandre Yutani Koseki +5 more
doaj
Recalcitrant Eyelid Lupus Treated With Topical Ruxolitinib
JEADV Clinical Practice, EarlyView.ABSTRACT Lupus of the eyelids, or lupus blepharitis, is a rare and localized form of chronic cutaneous lupus. The use of topical corticosteroids is limited in this sensitive area due to the risk of adverse events. We present a case of eyelid lupus, with histological confirmation, resistant to multiple lines of treatment, successfully treated with ...
Clémence Bertold +6 more
wiley +1 more source
Nail Toxicities Associated With Anticancer Therapies in Children
JEADV Clinical Practice, EarlyView.ABSTRACT Nail toxicities are a frequent yet often underrecognized component of dermatologic adverse events in children receiving anticancer therapies. Both conventional cytotoxic chemotherapy and newer targeted agents can affect the nail matrix, nail bed and periungual tissues, producing a broad spectrum of clinical manifestations that range from ...
Luca Rapparini, Michela Starace
wiley +1 more source
Allergology International, 2018 Background: In severe drug eruptions, precise evaluation of disease severity at an early stage is needed to start appropriate treatment. It is not always easy to diagnose these conditions at their early stage.
Takayoshi Komatsu-Fujii +7 more
doaj +1 more source